| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Heath Lukatch is Director at PCVX and has filed Form 4s across 2 companies. Heath Lukatch's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.3M at current prices.
Historically, Heath Lukatch's trades have earned a below-average insider score of 41/100 across 8 rated trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -28.9%.
The biggest single holding is PCVX (~$1.2M) as Director. The PCVX filings lean toward selling, a net 34,000 shares.
Heath Lukatch has 33 Form 4 filings on record from October 2015 to June 2026, across 2 companies: Director at Vaxcyte (PCVX), 2020–2026; Director at Inogen (INGN), 2015–2021.
The 80 reported transactions were 37 open-market sales, 21 option exercises, 10 option or other derivative awards and 9 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $86K and 17 sales worth about $4.2M.
The only open-market purchase was 2,000 shares of INGN at an average $43.01 on August 15, 2019, about $86K.
The largest open-market sale was 13,000 shares of PCVX at an average $63.76 on January 2, 2024, about $829K. Twelve months later PCVX was up 32%.
All 3 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 31, 2024 | PCVX Vaxcyte, Inc. | Director | Sale+OE10b5-1 | 5,000 | $71.50 | $357,500.00 | -47.1% | -15.2% | +28.7% | |
| Jan 29, 2024 | PCVX Vaxcyte, Inc. | Director | Sale+OE10b5-1 | 4,000 | $67.50 | $270,000.00 | -41.6% | -10.9% | +34.5% | |
| Jan 2, 2024 | PCVX Vaxcyte, Inc. | Director | Sale+OE10b5-1 | 13,000 | $63.76 | $828,915.03 | -69.8% | +6.0% | +32.3% | |
| Jan 10, 2023 | PCVX Vaxcyte, Inc. | Director | Sale+OE | 315 | $46.12 | $14,526.47 | -9.2% | -21.2% | +34.1% | |
| Dec 12, 2022 | PCVX Vaxcyte, Inc. | Director | Sale+OE | 335 | $43.93 | $14,717.13 | -9.7% | -14.5% | +29.7% | |
| Nov 10, 2022 | PCVX Vaxcyte, Inc. | Director | Sale+OE | 4,335 | $46.13 | $199,988.57 | -58.1% | +0.9% | +7.5% | |
| Oct 26, 2022 | PCVX Vaxcyte, Inc. | Director | Sale+OE | 7,015 | $36.90 | $258,856.65 | -69.2% | +10.6% | +18.3% | |
| Aug 15, 2019 | INGN Inogen Inc | Director | Buy | 2,000 | $43.01 | $86,020.00 | +57.5% | - | - | |
| Nov 6, 2018 | INGN Inogen Inc | Director | Sale+OE | 500 | $193.97 | $96,987.00 | -33.6% | - | - | |
| Oct 5, 2018 | INGN Inogen Inc | Director | Sale+OE | 500 | $218.23 | $109,114.50 | -33.6% | - | - |